Thistle Mary 4

What Happened
Thistle Mary, a director of Entrada Therapeutics (TRDA), received a derivative award of 19,000 shares on 2026-06-10. The reported acquisition price is $0.00 (no cash paid at grant). The award is reported as a derivative/award (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (appears timely — within the usual 2-business-day window).
• Shares granted: 19,000; reported price: $0.00; immediate cash value reported: $0.
• Shares owned after transaction: Not disclosed in the provided filing details.
• Footnote: The shares subject to this award vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the issuer's next annual meeting of stockholders.
• Transaction type: Derivative award (grant/award), not a sale or open-market purchase.

Context
Director awards like this are typically compensation-related and do not necessarily signal a buy or sell view by the insider. Because no cash was paid and vesting is contingent, the grant represents potential future equity if vesting conditions are met — not an immediate change in market exposure.